Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc. (VRPX) priced its initial public offering on Feb 18, 2021 at $10.00 per share, raising $18M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $49.5M. ThinkEquity was lead-left underwriter. Lowenstein Sandler advised the company and Sheppard Mullin advised the underwriters.

Virpax Pharmaceuticals, Inc. is a preclinical-stage biopharmaceutical company developing non-opioid, non-addictive pain products using new drug delivery systems. Its rights include Epoladerm, a topical spray film for acute musculoskeletal pain, and Probudur, an injectable liposomal gel for postoperative pain.

Status

IPO

Ticker

VRPX

Exchange

Nasdaq Capital Market

Priced

Feb 18, 2021

IPO price

$10.00

Raised

$18M

Market cap at IPO price

$49.5M

First filed

Oct 9, 2020

Underwriters

ThinkEquity

Company counsel

Lowenstein Sandler

Underwriters' counsel

Sheppard Mullin

Sector

Biotech & pharma

Country / state

PA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.